Regal Investment Advisors LLC Has $452,000 Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Regal Investment Advisors LLC lessened its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 38.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,715 shares of the biopharmaceutical company's stock after selling 11,138 shares during the quarter. Regal Investment Advisors LLC's holdings in Royalty Pharma were worth $452,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Jump Financial LLC bought a new position in shares of Royalty Pharma during the fourth quarter worth about $2,088,000. Bridgewater Associates LP bought a new position in shares of Royalty Pharma during the 4th quarter worth approximately $1,261,000. Portolan Capital Management LLC raised its holdings in shares of Royalty Pharma by 101.9% in the fourth quarter. Portolan Capital Management LLC now owns 344,185 shares of the biopharmaceutical company's stock valued at $8,780,000 after purchasing an additional 173,721 shares during the last quarter. Walleye Capital LLC acquired a new position in Royalty Pharma during the fourth quarter worth $641,000. Finally, Barclays PLC grew its position in Royalty Pharma by 17.6% in the fourth quarter. Barclays PLC now owns 363,308 shares of the biopharmaceutical company's stock valued at $9,269,000 after purchasing an additional 54,421 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Stock Performance

NASDAQ:RPRX traded up $0.19 on Tuesday, hitting $32.38. The company's stock had a trading volume of 476,715 shares, compared to its average volume of 3,243,349. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $18.67 billion, a P/E ratio of 22.33, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.20. The stock has a fifty day moving average of $32.56 and a two-hundred day moving average of $29.32.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on RPRX shares. Citigroup restated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research note on Tuesday, December 24th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.